Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
ID: 348274Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348274
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for research that enhances the diagnosis, management, and treatment of rare diseases, promoting collaborative, multi-site, patient-centric, translational, and clinical research. The RDCRC will focus on developing outcome measures that address unmet clinical trial readiness needs, thereby advancing the field of rare disease research. The estimated total program funding is $1,000,000, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare for a cooperative agreement under the U54 activity code, with an anticipated award date of July 1, 2025.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Forecast for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the R21 grant aimed at enhancing clinical trial readiness for rare diseases, disorders, and syndromes. This initiative seeks to support research projects that address critical needs in the field, such as the development of biomarkers and clinical outcome measures, which are essential for facilitating the transition of therapeutics and diagnostics into clinical trials. The opportunity is particularly significant as it aims to improve the success rates of clinical trials for rare diseases, which often face unique challenges. Interested small businesses are encouraged to begin forming collaborations and developing proposals, with the estimated synopsis posting date set for November 14, 2025, and applications expected to be accepted until February 16, 2026. For further inquiries, potential applicants can contact Dr. Alice Chen Grady at alice.chen2@nih.gov or by phone at 301-827-2015.
    Renewal of NIA Research Centers Collaborative Network (RCCN)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the renewal of the Research Centers Collaborative Network (RCCN), aimed at enhancing collaborations across its seven research centers focused on aging research. This initiative seeks to leverage NIH's significant investments by fostering interdisciplinary efforts and sustaining high-value activities, while also encouraging new initiatives such as pilot funding programs and enhanced mentoring infrastructure. Interested applicants, particularly those with expertise in aging research, are advised to prepare for this opportunity, with the estimated synopsis posting date on March 1, 2026, and a closing date for applications anticipated by May 25, 2026. For further inquiries, potential applicants can contact Amelia Karraker at amelia.karraker@nih.gov or by phone at 301-496-3131.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of Clinical Sites for the Undiagnosed Diseases Network (U01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for a Limited Competition aimed at continuing the support for Clinical Sites within the Undiagnosed Diseases Network (UDN). This initiative is specifically designed for institutions and Program Directors/Principal Investigators who have previously received NIH funding under the UDN program, allowing them to compete for an additional year of funding to enhance their participation, establish collaborations, and develop sustainability plans as the network transitions into a national resource. The total estimated program funding is $6.5 million, with an award ceiling of $400,000 and an expected 11 awards to be made. Interested applicants should note that the FOA is anticipated to be published in August 2022, with applications due by September 2022. For further inquiries, potential applicants can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Forecast to Publish a Notice of Funding Opportunity Announcement for the Research Centers in Minority Institutions (RCMI) Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Research Centers in Minority Institutions (RCMI) Coordinating Center, aimed at enhancing research capacity in minority health and health disparities. This initiative seeks applications from private institutions of higher education that have received limited NIH funding and offer doctorate degrees in health-related fields, with the goal of supporting collaborative research and improving health outcomes in underserved communities. The estimated total program funding is $5 million, with one award anticipated, and interested applicants can reach out to Dr. Rada K. Dagher at rada.dagher@nih.gov or (301) 451-2187 for further information. Key dates include an estimated synopsis post date of September 24, 2025, and a projected award date of March 25, 2026.
    Forecast to Publish a Funding Opportunity Announcement for Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Research Centers in Minority Institutions (RCMI) program, aimed at enhancing research capacity in health sciences at less research-intensive institutions. Eligible applicants must be domestic institutions in the U.S. and its territories that have received limited NIH support in recent years and offer doctorate degrees in health-related fields. The program, which has an estimated total funding of $22 million and anticipates awarding five grants, focuses on expanding research capabilities and fostering collaborations to address health disparities. Interested parties can reach out to Dr. Nathan Stinson at stinsonn@mail.nih.gov or by phone at 301-594-8704 for further information, with the application process expected to open in late 2025.
    Forecast to Renew the Notice of Funding Opportunity Announcement for the Multiple Chronic Disease Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is set to renew the Notice of Funding Opportunity (NOFO) for the Multiple Chronic Disease Research Centers, aimed at enhancing research on the prevention, diagnosis, treatment, and management of multiple chronic diseases (MCDs). This initiative will support both existing and new regional comprehensive research centers that focus on innovative strategies and interventions to improve health outcomes, particularly among populations facing health disparities. With an estimated total program funding of $55 million and the expectation of awarding 11 grants, potential applicants are encouraged to begin forming collaborations and developing projects, as applications are not currently being solicited. For further inquiries, interested parties may contact Dr. Dolly Penn at dolly.penn@nih.gov or by phone at 301-496-8676, with key deadlines including an estimated synopsis post date of May 16, 2025, and a close date of July 25, 2025.